Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Korea.
Cancer Gene Ther. 2013 Feb;20(2):82-7. doi: 10.1038/cgt.2012.88. Epub 2013 Jan 11.
We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation of TRAIL receptors, which can sustain TRAIL-induced apoptosis for a long time. Here, we designed a replication-defective adenovirus expressing the short hairpin RNA (shRNA) against c-Cbl to test the possibility of developing a cancer gene therapy that can act as a sensitizer of TRAIL. As expected from the results of our previous study that used a stable cell line with downregulated c-Cbl, infection with the c-Cbl shRNA-expressing adenovirus led to an increase in the death receptor 4 (DR4) and DR5 levels, which is known to be a cause for the increase of TRAIL-induced apoptosis. In conclusion, we demonstrated that c-Cbl shRNA-expressing adenovirus is able to sensitize TRAIL-induced apoptosis in vivo as well as in vitro.
我们之前已经证明 Casitas B- 细胞淋巴瘤(c-Cbl)的下调可以通过两种不同的方式使肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的凋亡敏感化。一种方式是阻止 TRAIL 受体的快速降解,这可以使 TRAIL 诱导的凋亡持续很长时间。在这里,我们设计了一种表达针对 c-Cbl 的短发夹 RNA(shRNA)的复制缺陷型腺病毒,以测试开发一种可以作为 TRAIL 增敏剂的癌症基因治疗的可能性。正如我们之前使用下调 c-Cbl 的稳定细胞系进行的研究结果所预期的那样,感染表达 c-Cbl shRNA 的腺病毒导致死亡受体 4(DR4)和 DR5 水平增加,这被认为是 TRAIL 诱导凋亡增加的原因。总之,我们证明了 c-Cbl shRNA 表达腺病毒能够在体内和体外使 TRAIL 诱导的凋亡敏感化。